Mutual Alleges Mucinex Monopoly In Extended-Release Guaifenesin
This article was originally published in The Tan Sheet
Mutual Pharmaceutical alleges in an antitrust suit that RB attempts to monopolize the extended-release guaifenesin OTC category with its Mucinex product. The suit says Mutual has lost “tens of millions” due to RB's failure to honor a contract to supply an “authorized generic” of the product.
You may also be interested in...
The private labeler clears a Reckitt Benckiser legal hurdle and will launch generic Mucinex (guaifenesin) by April. Watson has filed ANDAs for three Mucinex products and could be a good strategic partner for Perrigo, an analyst suggests.
A settlement agreement granting United Research Labs/Mutual Pharmaceuticals a conditional license for certain guaifenesin products could help Adams Respiratory Therapeutics fend off other potential generic competition for its Mucinex brand
“There’s a heightened need for products that deliver against health, hygiene and clean home concerns and a willingness to spend just a little bit more to ensure that I’m using a product that I know and trust,” says CFO Jon Moeller